Review

rabbit antibody against rac2 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech rabbit antibody against rac2

<t>RAC2</t> expression is upregulated in ccRCC, and is associated with various clinicopathological parameters in ccRCC tissues. The mRNA expression levels of RAC2 were obtained from TCGA dataset, which contained 72 adjacent normal tissues and 534 ccRCC tissues. (A) RAC2 expression was higher in the ccRCC tissues than in the adjacent normal tissues in the 72 paired tissues from patients with ccRCC. The mRNA expression levels of RAC2 were increased in (B) ccRCC tissues than in normal tissues in TCGA, (C) Gumz renal database, (D) Lenburg renal dataset, (E) Jones renal dataset and (F) Yusenko renal dataset. The high expression of RAC2 mRNA was associated with various clinicopathological factors: (G) T stage, (H) lymph node metastasis, (I) distant metastases, (J) TNM stage and (K) G grade. **** P<0.0001; *** P<0.001; ** P<0.01. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; TCGA, The Cancer Genome Atlas; TNM, Tumor-Node-Metastasis.

Rabbit Antibody Against Rac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+antibody+against+rac2/pmc06685597-115-7-12?v=Proteintech
Average 94 stars, based on 27 article reviews

rabbit antibody against rac2 - by Bioz Stars, 2026-07

94/100 stars

Images

1) Product Images from "RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma"

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

Journal: International Journal of Oncology

doi: 10.3892/ijo.2019.4849

RAC2 expression is upregulated in ccRCC, and is associated with various clinicopathological parameters in ccRCC tissues. The mRNA expression levels of RAC2 were obtained from TCGA dataset, which contained 72 adjacent normal tissues and 534 ccRCC tissues. (A) RAC2 expression was higher in the ccRCC tissues than in the adjacent normal tissues in the 72 paired tissues from patients with ccRCC. The mRNA expression levels of RAC2 were increased in (B) ccRCC tissues than in normal tissues in TCGA, (C) Gumz renal database, (D) Lenburg renal dataset, (E) Jones renal dataset and (F) Yusenko renal dataset. The high expression of RAC2 mRNA was associated with various clinicopathological factors: (G) T stage, (H) lymph node metastasis, (I) distant metastases, (J) TNM stage and (K) G grade. **** P<0.0001; *** P<0.001; ** P<0.01. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; TCGA, The Cancer Genome Atlas; TNM, Tumor-Node-Metastasis.

Figure Legend Snippet: RAC2 expression is upregulated in ccRCC, and is associated with various clinicopathological parameters in ccRCC tissues. The mRNA expression levels of RAC2 were obtained from TCGA dataset, which contained 72 adjacent normal tissues and 534 ccRCC tissues. (A) RAC2 expression was higher in the ccRCC tissues than in the adjacent normal tissues in the 72 paired tissues from patients with ccRCC. The mRNA expression levels of RAC2 were increased in (B) ccRCC tissues than in normal tissues in TCGA, (C) Gumz renal database, (D) Lenburg renal dataset, (E) Jones renal dataset and (F) Yusenko renal dataset. The high expression of RAC2 mRNA was associated with various clinicopathological factors: (G) T stage, (H) lymph node metastasis, (I) distant metastases, (J) TNM stage and (K) G grade. **** P<0.0001; *** P<0.001; ** P<0.01. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; TCGA, The Cancer Genome Atlas; TNM, Tumor-Node-Metastasis.

Techniques Used: Expressing

Association between RAC2 mRNA expression and clinicopathological parameters of patients with clear cell renal cell carcinoma.

Figure Legend Snippet: Association between RAC2 mRNA expression and clinicopathological parameters of patients with clear cell renal cell carcinoma.

Techniques Used: Expressing

High RAC2 mRNA expression is associated with poor OS in patients with ccRCC. Patient samples from The Cancer Genome Atlas were separated into two groups: Those with low RAC2 expression and those with high RAC2 expression. (A) OS of patients with ccRCC was associated with RAC2 expression. OS subanalysis in regards to RAC2 expression was conducted in subgroups of patients with ccRCC: (B) Male, (C) age ≥60 years and (D) T1 + T2 stage. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; OS, overall survival.

Figure Legend Snippet: High RAC2 mRNA expression is associated with poor OS in patients with ccRCC. Patient samples from The Cancer Genome Atlas were separated into two groups: Those with low RAC2 expression and those with high RAC2 expression. (A) OS of patients with ccRCC was associated with RAC2 expression. OS subanalysis in regards to RAC2 expression was conducted in subgroups of patients with ccRCC: (B) Male, (C) age ≥60 years and (D) T1 + T2 stage. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; OS, overall survival.

Techniques Used: Expressing

RAC2 expression may be a diagnostic biomarker in patients with ccRCC. (A) RAC2 effectively discriminated between ccRCC and paired normal tissues (AUC 0.9095; P<0.0001). Receiver operating characteristic curve subanalysis was performed with respect to the following subgroups of patients with ccRCC: (B) G grade, (C) T stage, (D) lymph node metastasis, (E) distant metastases, (F) Tumor-Node-Metastasis stage, (G) overal survival and (H) disease free survive. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; AUC, area under the curve; OS, overall survival; DFS, disease-free survival.

Figure Legend Snippet: RAC2 expression may be a diagnostic biomarker in patients with ccRCC. (A) RAC2 effectively discriminated between ccRCC and paired normal tissues (AUC 0.9095; P<0.0001). Receiver operating characteristic curve subanalysis was performed with respect to the following subgroups of patients with ccRCC: (B) G grade, (C) T stage, (D) lymph node metastasis, (E) distant metastases, (F) Tumor-Node-Metastasis stage, (G) overal survival and (H) disease free survive. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; AUC, area under the curve; OS, overall survival; DFS, disease-free survival.

Techniques Used: Expressing, Diagnostic Assay, Biomarker Discovery

RAC2 was up-regulated in RCC cells and tissues. (A and B) Reverse transcription-quantitative PCR assays of RAC2 mRNA expression in normal renal tubular epithelial cells (HK-2) and renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O), and in 50 paired tissue samples of patients with ccRCC. (C and D) Western blot assays of RAC2 expression in normal renal tubular epithelial cells (HK-2) and in renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O) and in 50 paired tissue samples of ccRCC patients. (E) Immunohistochemistry for RAC2 expression in ccRCC tissues, adjacent normal tissues and renal angiomyolipoma tissues. The inset images are the lower magnification of the same tissue as that presented in the larger image of each set. Magnification, ×40 and ×200. RAC2 expression was normalized to β-actin expression. The values of each group are presented as the mean ± standard deviation. Bars represented the means of three independent experiments. **** P<0.0001; ** P<0.01 vs. HK-2. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma.

Figure Legend Snippet: RAC2 was up-regulated in RCC cells and tissues. (A and B) Reverse transcription-quantitative PCR assays of RAC2 mRNA expression in normal renal tubular epithelial cells (HK-2) and renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O), and in 50 paired tissue samples of patients with ccRCC. (C and D) Western blot assays of RAC2 expression in normal renal tubular epithelial cells (HK-2) and in renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O) and in 50 paired tissue samples of ccRCC patients. (E) Immunohistochemistry for RAC2 expression in ccRCC tissues, adjacent normal tissues and renal angiomyolipoma tissues. The inset images are the lower magnification of the same tissue as that presented in the larger image of each set. Magnification, ×40 and ×200. RAC2 expression was normalized to β-actin expression. The values of each group are presented as the mean ± standard deviation. Bars represented the means of three independent experiments. **** P<0.0001; ** P<0.01 vs. HK-2. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma.

Techniques Used: Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Immunohistochemistry, Standard Deviation

RAC2 regulates certain tumor-related pathways. Enrichment curves are shown for activated gene sets related to the (A) Toll like receptor, (B) JAK STAT and (C) P53 signaling pathways, (D) apoptosis, and the (E) cell cycle and (F) MAPK signal pathways. RAC2, Rac family small GTPase 2; NES, normalized enrichment score; FDR, false discovery rate; JAK, Janus kinases; STAT, signal transducer and activator of transcription proteins; MAPK, mitogen-activated protein kinase.

Figure Legend Snippet: RAC2 regulates certain tumor-related pathways. Enrichment curves are shown for activated gene sets related to the (A) Toll like receptor, (B) JAK STAT and (C) P53 signaling pathways, (D) apoptosis, and the (E) cell cycle and (F) MAPK signal pathways. RAC2, Rac family small GTPase 2; NES, normalized enrichment score; FDR, false discovery rate; JAK, Janus kinases; STAT, signal transducer and activator of transcription proteins; MAPK, mitogen-activated protein kinase.

Techniques Used: Protein-Protein interactions

RAC2 promotes the proliferation, invasion and migration of RCC cell lines in vitro . (A and B) Reverse transcription-qauntitative PCR and western blotting assays of RAC2 knockdown in ACHN and 786-O cells; β-actin was used as a loading control. (C and D) Cell counting kit-8 assays detected the effects of RAC2 knockdown on the proliferation of ACHN and 786-O cells. (E-H) Representative images of migration and invasion assays performed using ACHN and 786-O cells (magnification, ×100). Data are presented as the mean ± standard deviation from three independent experiments. **** P<0.0001; *** P<0.001; ** P<0.01 and * P<0.05 vs. si-NC. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; NC, negative control; si-RNA, small interfering RNA; OD value, optical density value.

Figure Legend Snippet: RAC2 promotes the proliferation, invasion and migration of RCC cell lines in vitro . (A and B) Reverse transcription-qauntitative PCR and western blotting assays of RAC2 knockdown in ACHN and 786-O cells; β-actin was used as a loading control. (C and D) Cell counting kit-8 assays detected the effects of RAC2 knockdown on the proliferation of ACHN and 786-O cells. (E-H) Representative images of migration and invasion assays performed using ACHN and 786-O cells (magnification, ×100). Data are presented as the mean ± standard deviation from three independent experiments. **** P<0.0001; *** P<0.001; ** P<0.01 and * P<0.05 vs. si-NC. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; NC, negative control; si-RNA, small interfering RNA; OD value, optical density value.

Techniques Used: Migration, In Vitro, Reverse Transcription, Western Blot, Knockdown, Control, Cell Counting, Standard Deviation, Negative Control, Small Interfering RNA

Image Search Results

Overall survival and the expression levels of Rho/Rac family genes in DLBCL. Kaplan–Meier curve of overall survival for individual member ( A ) RAC1, ( B ) RAC2, ( C ) RND1, ( D ) CDC42, ( E ) RHOQ, ( F ) RHOF; HR, hazard ratio.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: Overall survival and the expression levels of Rho/Rac family genes in DLBCL. Kaplan–Meier curve of overall survival for individual member ( A ) RAC1, ( B ) RAC2, ( C ) RND1, ( D ) CDC42, ( E ) RHOQ, ( F ) RHOF; HR, hazard ratio.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing

Correlation between the expression of Rho/Rac family members’ and BTK. ( A ) Co-expression heatmap of Rho/Rac family genes and BTK; ( B ) Scatter diagram demonstrated the correlation between BTK and RAC1 , ( C ) CDC42, ( D ) RHOF and ( E ) RHOQ. * p <0.05; ** p < 0.01; *** p < 0.001.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: Correlation between the expression of Rho/Rac family members’ and BTK. ( A ) Co-expression heatmap of Rho/Rac family genes and BTK; ( B ) Scatter diagram demonstrated the correlation between BTK and RAC1 , ( C ) CDC42, ( D ) RHOF and ( E ) RHOQ. * p <0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing

RAC1 expression levels in 18 different types of tumor tissues and paired adjacent normal tissues. * p < 0.05; ** p < 0.01; *** p < 0.001; ns: non-significance. BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine Corpus Endometrial Carcinoma.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: RAC1 expression levels in 18 different types of tumor tissues and paired adjacent normal tissues. * p < 0.05; ** p < 0.01; *** p < 0.001; ns: non-significance. BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine Corpus Endometrial Carcinoma.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing

Correlation between RAC1 expression and DLBCL clinical characteristics.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: Correlation between RAC1 expression and DLBCL clinical characteristics.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing

Logistic analyses of RAC1 expression and clinical characteristics of DLBCL.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: Logistic analyses of RAC1 expression and clinical characteristics of DLBCL.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing

RAC1 expression in patients with DLBCL according to different clinical stages.( A ) In the TCGA-DLBC dataset, RAC1 was upregulated in stage I/II as compared with that in stage III/IV. ( B ) RAC1 protein IHC staining in lymphadenitis and ( C ) DLBCL stage II, ( D ) stage III, ( E ) stage IV. Magnification 20 × 20, * p < 0.05. The staining of 3,3′-diaminobenzidine (DAB) was employed for RAC1 expression (yellow and brown) compared to negative sample (blue). Scale bar (bottom, right) = 100 μm.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: RAC1 expression in patients with DLBCL according to different clinical stages.( A ) In the TCGA-DLBC dataset, RAC1 was upregulated in stage I/II as compared with that in stage III/IV. ( B ) RAC1 protein IHC staining in lymphadenitis and ( C ) DLBCL stage II, ( D ) stage III, ( E ) stage IV. Magnification 20 × 20, * p < 0.05. The staining of 3,3′-diaminobenzidine (DAB) was employed for RAC1 expression (yellow and brown) compared to negative sample (blue). Scale bar (bottom, right) = 100 μm.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques: Expressing, Immunohistochemistry, Staining

Cox regression analyses of clinical features associated with DLBCL overall survival.

Journal: Cells

Article Title: RAC1 , a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

doi: 10.3390/cells11244039

Figure Lengend Snippet: Cox regression analyses of clinical features associated with DLBCL overall survival.

Article Snippet: Sections from paraffin-embedded tissues were then immunostained with a rabbit polyclonal antibody against RAC1 (dilution: 1:300, Bioss, BJ, CHN).

Techniques:

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: RAC2 expression is upregulated in ccRCC, and is associated with various clinicopathological parameters in ccRCC tissues. The mRNA expression levels of RAC2 were obtained from TCGA dataset, which contained 72 adjacent normal tissues and 534 ccRCC tissues. (A) RAC2 expression was higher in the ccRCC tissues than in the adjacent normal tissues in the 72 paired tissues from patients with ccRCC. The mRNA expression levels of RAC2 were increased in (B) ccRCC tissues than in normal tissues in TCGA, (C) Gumz renal database, (D) Lenburg renal dataset, (E) Jones renal dataset and (F) Yusenko renal dataset. The high expression of RAC2 mRNA was associated with various clinicopathological factors: (G) T stage, (H) lymph node metastasis, (I) distant metastases, (J) TNM stage and (K) G grade. **** P<0.0001; *** P<0.001; ** P<0.01. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; TCGA, The Cancer Genome Atlas; TNM, Tumor-Node-Metastasis.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: Association between RAC2 mRNA expression and clinicopathological parameters of patients with clear cell renal cell carcinoma.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: High RAC2 mRNA expression is associated with poor OS in patients with ccRCC. Patient samples from The Cancer Genome Atlas were separated into two groups: Those with low RAC2 expression and those with high RAC2 expression. (A) OS of patients with ccRCC was associated with RAC2 expression. OS subanalysis in regards to RAC2 expression was conducted in subgroups of patients with ccRCC: (B) Male, (C) age ≥60 years and (D) T1 + T2 stage. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; OS, overall survival.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: RAC2 expression may be a diagnostic biomarker in patients with ccRCC. (A) RAC2 effectively discriminated between ccRCC and paired normal tissues (AUC 0.9095; P<0.0001). Receiver operating characteristic curve subanalysis was performed with respect to the following subgroups of patients with ccRCC: (B) G grade, (C) T stage, (D) lymph node metastasis, (E) distant metastases, (F) Tumor-Node-Metastasis stage, (G) overal survival and (H) disease free survive. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; AUC, area under the curve; OS, overall survival; DFS, disease-free survival.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Expressing, Diagnostic Assay, Biomarker Discovery

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: RAC2 was up-regulated in RCC cells and tissues. (A and B) Reverse transcription-quantitative PCR assays of RAC2 mRNA expression in normal renal tubular epithelial cells (HK-2) and renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O), and in 50 paired tissue samples of patients with ccRCC. (C and D) Western blot assays of RAC2 expression in normal renal tubular epithelial cells (HK-2) and in renal cancer cell lines (A498, ACHN, CAKI-1, OSRC-2, 786-O) and in 50 paired tissue samples of ccRCC patients. (E) Immunohistochemistry for RAC2 expression in ccRCC tissues, adjacent normal tissues and renal angiomyolipoma tissues. The inset images are the lower magnification of the same tissue as that presented in the larger image of each set. Magnification, ×40 and ×200. RAC2 expression was normalized to β-actin expression. The values of each group are presented as the mean ± standard deviation. Bars represented the means of three independent experiments. **** P<0.0001; ** P<0.01 vs. HK-2. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Immunohistochemistry, Standard Deviation

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: RAC2 regulates certain tumor-related pathways. Enrichment curves are shown for activated gene sets related to the (A) Toll like receptor, (B) JAK STAT and (C) P53 signaling pathways, (D) apoptosis, and the (E) cell cycle and (F) MAPK signal pathways. RAC2, Rac family small GTPase 2; NES, normalized enrichment score; FDR, false discovery rate; JAK, Janus kinases; STAT, signal transducer and activator of transcription proteins; MAPK, mitogen-activated protein kinase.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Protein-Protein interactions

Journal: International Journal of Oncology

Article Title: RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

doi: 10.3892/ijo.2019.4849

Figure Lengend Snippet: RAC2 promotes the proliferation, invasion and migration of RCC cell lines in vitro . (A and B) Reverse transcription-qauntitative PCR and western blotting assays of RAC2 knockdown in ACHN and 786-O cells; β-actin was used as a loading control. (C and D) Cell counting kit-8 assays detected the effects of RAC2 knockdown on the proliferation of ACHN and 786-O cells. (E-H) Representative images of migration and invasion assays performed using ACHN and 786-O cells (magnification, ×100). Data are presented as the mean ± standard deviation from three independent experiments. **** P<0.0001; *** P<0.001; ** P<0.01 and * P<0.05 vs. si-NC. RAC2, Rac family small GTPase 2; ccRCC, clear cell renal cell carcinoma; NC, negative control; si-RNA, small interfering RNA; OD value, optical density value.

Article Snippet: Tissue sections were then incubated with a rabbit antibody against RAC2 (1:100; ProteinTech Group, Inc., cat. no. 60077-1-Ig) overnight at 4°C.

Techniques: Migration, In Vitro, Reverse Transcription, Western Blot, Knockdown, Control, Cell Counting, Standard Deviation, Negative Control, Small Interfering RNA

Review

Structured Review

Images

1) Product Images from "RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma"

Similar Products

Image Search Results